[Metabolism Clinical and Experimental] Researchers studied 63 individuals undergoing partial pancreatectomy who underwent preoperative OGTT with model-based assessment of β cell function and provided pancreatic tissue for ex vivo islet isolation and glucose stimulation.

[Cancer Letters] Scientists established Foxa1-orchestrated enhancer reprogramming as a fundamental mechanism of gemcitabine resistance and unveil a promising epigenetic therapy to restore treatment efficacy in PDAC.

[Diabetes] Scientists demonstrated that replication introduces a window of genomic vulnerability in both α- and β-cells during neonatal growth, with α-cells exhibiting higher replication rates and DNA damage.

[Molecular Cell] Investigators demonstrated that histone deacetylase 5 (HDAC5) mediates the deacetylation of forkhead box A1 (FOXA1) at lysine residue 270, leading to repression of FOXA1’s global chromatin occupancy.

[Cancer Immunology Research] The authors establish cancer-associated fibroblast-stratified ductal spatial architecture as a fundamental determinant of immune exclusion in PDAC.

[Cancer Letters] Using a mCherry-tagged Gstt1 reporter system in metastatic murine PDAC cells, investigators enriched for Gstt1^High cells and observed increased tumor sphere formation, accompanied by upregulation of stemness-associated genes including PROM1 (CD133) and activation of Wnt and FGF signaling pathways.

[Seminars in Immunology] Scientists discuss how ferroptosis shapes immune responses in pancreatitis and pancreatic cancer and examine the factors that determine whether it promotes inflammation, antitumor immunity, or immune tolerance.

[Revolution Medicines, Inc.] Revolution Medicines, Inc. announced that the US FDA accepted for review the company’s New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.

[Journal for Immunotherapy of Cancer] Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.

[Cancer Letters] The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.